ErlySign, the Nagpur-based biotech startup developing salivary biomarker–based screening test for early-stage oral cancer, has announced the appointment of Vishal Kumar as Vice President – Business.
Vishal brings over a decade of experience across Healthcare, Health-tech, and Technology, with a B.Tech from IIT Kharagpur. He is known for his ability to scale business functions and drive organisational transformation. He has led high-impact teams, shaped growth strategies, and built partnerships that strengthen healthcare delivery across diverse ecosystems.
Before joining ErlySign, Vishal held leadership roles that sharpened his strategic, operational, and commercial acumen. At Tata 1mg, he led the Hospital and Corporate Health & Wellness verticals, driving key accounts and significantly accelerating both top-line and bottom-line growth over the past five years. He also forged major institutional partnerships and spearheaded large-scale project implementations.
In his new role at ErlySign, Vishal will lead business growth, strategic partnerships, and market expansion, strengthening the company’s vision of becoming a global leader in painless, affordable early cancer detection. His focus will be on scaling operations, forging high-impact alliances, and accelerating ErlySign’s presence across India and international markets.
Shubhendra Singh, CEO at ErlySign, said, “As ErlySign expands its mission of making early cancer detection accessible and affordable, strong leadership becomes essential. Vishal’s blend of operational insight, market understanding, and an ability to build for scale aligns perfectly with where we’re headed. We’re excited to have him join us at this important moment.”
Vishal Kumar said, “ErlySign’s mission is powerful and urgent. A simple, non-invasive saliva test that can flag cancer risk early has the potential to shift the entire paradigm of preventive healthcare. I am excited to work with the founders and the wider team to take this solution to new markets, both in India and globally and build partnerships that accelerate early detection for millions.”
